Ophthalmic medical device company Vital Art and Science (VAS) unveiled the mVT Service, an innovative medical device and physician portal that tracks the progression of vision damaging diseases such as age related macular degeneration and diabetic retinopathy. The service, available only by prescription, works with a companion app that can be used on any Apple smartphone or tablet. Patient test data are automatically uploaded to a Physician’s Portal where licensed eye-care professionals can monitor all patient test results.
The new mVT Service is low cost, easy to use, and allows patients to test their vision at home. Patients take a simple 4-6 minute self-test, performed on the timetable recommended by the doctor (usually twice a week). The results are then automatically delivered to the Physician Portal for review and analysis.
The mVT Service, which includes the app and the Physician’s Portal, is available by prescription only and costs patients $8.95/month.The service relies on proprietary algorithms to assess visual function and detect changes between physician visits. A significant change in the eye condition sends an alert to the doctor who will determine if an earlier intervention is required, such as new appointment, assessment or treatment.
“Our clinical trials have confirmed that the results from this convenient home test correlate well with in-office physician assessment and can potentially improve clinical outcomes by bringing in patients for earlier-than-planned examination and possibly treatment,” stated Mike Bartlett, company president. “Compliance with the prescribed mVT use is very high and patients feel more engaged in the management of their disease. Both patients and doctors appreciate the convenience.”
The mVT Service, which includes the app and the Physician’s Portal, is available by prescription only and costs patients $8.95/month.
VAS is currently reviewing strategic partnerships and other opportunities with the mVT Service.
Age related macular degeneration is the leading cause of blindness for people over 60, and diabetic retinopathy vision loss continues to grow with the increasing prevalence of diabetes.